| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18402906 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 118 journal articles in the PubMed database | Email to a friend | | |
| Lassen MR, Dahl O, Mismetti P, et al.
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Am Coll Cardiol 2008 Apr 15; 51(15):1498-504.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Eriksson BI, Borris L, Dahl OE, et al.
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. [Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2006 Jan; 4(1):121-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Fisher WD, Eriksson BI, Bauer KA, et al.
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. [Journal Article]
Thromb Haemost 2007 Jun; 97(6):931-7.
Abstract | Full Citation | Find Related Articles | | Turpie AG, Gallus AS, Hoek JA
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
N Engl J Med 2001 Mar 1; 344(9):619-25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Turpie AG, Bauer KA, Eriksson BI, et al.
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. [Journal Article, Meta-Analysis]
Arch Intern Med 2002 Sep 9; 162(16):1833-40.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Agnelli G, Haas S, Ginsberg JS, et al.
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. [Journal Article]
J Thromb Haemost 2007 Apr; 5(4):746-53.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Borris LC, Friedman RJ, et al.
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. [Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
N Engl J Med 2008 Jun 26; 358(26):2765-75.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Eriksson BI, Agnelli G, Cohen AT, et al.
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2003 Dec; 1(12):2490-6.
Abstract | Full Citation | Find Related Articles | | Eriksson BI, Dahl OE, Büller HR, et al.
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. [Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Thromb Haemost 2005 Jan; 3(1):103-11.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
